A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration, Choroidal Neovascularization
About this trial
This is an interventional treatment trial for Age-Related Macular Degeneration
Eligibility Criteria
Inclusion Criteria: Active AMD with Subfoveal CNV (classic and/or occult CNV) CNV lesion thickness >/= 250um by OCT assessment Visual acuity in study eye of </= 20/100 but not worse than 20/800 Not eligible for or refused standard treatment Exclusion Criteria: Females of childbearing potential Other causes of CNV including pathologic myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis Any intraocular surgery or treatment of AMD with Visudyne within 3 months of study entry CNV lesion >/= 12 MPS disc area
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
1
2
3
4
5
6
Single intravitreal injection
Single intravitreal injection
Single intravitreal injection
Single intravitreal injection
Single intravitreal injection
Single intravitreal injection